CLOS
AXDX

Compagnie Lombard Odier SCmA’s Accelerate Diagnostics AXDX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,400
Closed -$314K – 644
2017
Q3 		$314K Buy
+1,400
New +$344K 0.01% 313

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Compagnie Lombard Odier SCmA's AXDX Position: Q4 2017 in Review

Compagnie Lombard Odier SCmA sold out of Accelerate Diagnostics (AXDX) in Q4 2017, closing a stake of 1,400 shares — an estimated $314K sold.

Compagnie Lombard Odier SCmA first reported a position in AXDX in Q3 2017 and held it in 1 quarter. The position peaked at $314K in Q3 2017. 117 funds tracked by Wall St. Rank hold AXDX as of Q4 2017.

  • Compagnie Lombard Odier SCmA reported no remaining Accelerate Diagnostics position as of Q4 2017 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 1,400 Accelerate Diagnostics shares in Q4 2017, an estimated $314K.
  • Compagnie Lombard Odier SCmA first reported a position in Accelerate Diagnostics in Q3 2017 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Accelerate Diagnostics position peaked at $314K in Q3 2017.
  • 117 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2017, filed 13 Feb 2018.